ES2179096T3 - Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped. - Google Patents

Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped.

Info

Publication number
ES2179096T3
ES2179096T3 ES95908628T ES95908628T ES2179096T3 ES 2179096 T3 ES2179096 T3 ES 2179096T3 ES 95908628 T ES95908628 T ES 95908628T ES 95908628 T ES95908628 T ES 95908628T ES 2179096 T3 ES2179096 T3 ES 2179096T3
Authority
ES
Spain
Prior art keywords
interleucine
guest
prevent reaction
graft against
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95908628T
Other languages
English (en)
Inventor
Stanley F Wolf
Megan Sykes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Genetics Institute LLC
Original Assignee
General Hospital Corp
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Genetics Institute LLC filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2179096T3 publication Critical patent/ES2179096T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE PRESENTA EL USO DE LA INTERLEUQUINA-12 PARA PREVENIR, MEJORAR Y TRATAR INJERTOS CONTRA ENFERMEDADES DEL ANFITRION EN UN MAMIFERO EN NECESIDAD DE DICHO TRATAMIENTO.
ES95908628T 1994-01-21 1995-01-20 Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped. Expired - Lifetime ES2179096T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/186,529 US5573764A (en) 1994-01-21 1994-01-21 Use of interleukin-12 to prevent graft versus host disease

Publications (1)

Publication Number Publication Date
ES2179096T3 true ES2179096T3 (es) 2003-01-16

Family

ID=22685309

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95908628T Expired - Lifetime ES2179096T3 (es) 1994-01-21 1995-01-20 Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped.

Country Status (14)

Country Link
US (2) US5573764A (es)
EP (1) EP0739212B1 (es)
JP (1) JP3825043B2 (es)
AT (1) ATE215380T1 (es)
AU (1) AU698410B2 (es)
CA (1) CA2181568C (es)
DE (1) DE69526206T2 (es)
DK (1) DK0739212T3 (es)
ES (1) ES2179096T3 (es)
IL (1) IL112373A (es)
PT (1) PT739212E (es)
TW (1) TW349021B (es)
WO (1) WO1995019786A1 (es)
ZA (1) ZA95463B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
WO1997016203A1 (en) * 1995-11-01 1997-05-09 Genetics Institute, Inc. Methods for administration of il-12
CA2268276A1 (en) * 1996-10-18 1998-04-30 Jeff Nordstrom Gene expression and delivery systems and uses
EP0956301A2 (en) * 1996-10-18 1999-11-17 Valentis Inc. Il-12 gene expression and delivery systems and uses
WO1998034635A1 (en) * 1997-02-07 1998-08-13 The Wistar Institute Methods and compositions for the inhibition of interleukin-12 production
DE69825395T2 (de) * 1997-05-16 2005-01-13 Toray Industries, Inc. Medikament, behandlungsmethode, prophylaktikum und prophylaxe gegen immunologische erkrankungen von hunden und katzen
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US20040241153A1 (en) * 2001-08-31 2004-12-02 Fowler Daniel H. Methods of generating human cd4+ th1 cells
US20040175827A1 (en) * 2001-07-02 2004-09-09 Fowler Daniel H. Methods of generating human cd4+ th2 cells and uses thereof
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
US20040258661A1 (en) * 2001-10-31 2004-12-23 Daniel Fowler Generation of use of tc1 and tc2 cells
DE10248141B4 (de) * 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
US7939058B2 (en) * 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
RU2484132C2 (ru) * 2007-10-08 2013-06-10 Интрексон Корпорейшн Модифицированные дендритные клетки и их применение в лечении злокачественных опухолей
US20100272863A1 (en) * 2009-04-24 2010-10-28 Griebel Jonathan M Soft shaped tortillas
CA2800348C (en) 2010-05-18 2020-07-21 Lena A. Basile Il-12 formulations for enhancing hematopoiesis
US9925246B2 (en) 2011-06-13 2018-03-27 Neumedicines, Inc. Mitigation of cutaneous injury with IL-12
US20140178335A1 (en) 2011-07-27 2014-06-26 Neumedicines, Inc. Use of il-12 to generate endogenous erythropoietin
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
CA2850575C (en) * 2011-10-11 2020-12-15 Universitat Zurich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
US9616106B2 (en) 2012-01-18 2017-04-11 Neumedicines, Inc. IL-12 for radiation protection and radiation-induced toxicity mitigation
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
IL297186A (en) * 2020-04-17 2022-12-01 Univ Leland Stanford Junior Engineered il-12 and il-23 polypeptides and uses thereof
EP4228610A1 (en) * 2020-10-13 2023-08-23 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
EP4419545A4 (en) 2021-10-20 2025-10-22 Synthekine Inc HETERODIMERIC FC CYTOKINES AND THEIR USES
JP2025503454A (ja) * 2021-12-17 2025-02-04 ウィリアム マーシュ ライス ユニバーシティ Ｉｌ－１２を発現するカプセル化細胞及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131524A1 (en) * 1992-03-04 1993-09-16 Maria-Grazia Roncarolo Use of interleukin-10 to suppress graft-vs.-host disease
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease

Also Published As

Publication number Publication date
AU698410B2 (en) 1998-10-29
ATE215380T1 (de) 2002-04-15
CA2181568A1 (en) 1995-07-27
AU1687595A (en) 1995-08-08
DE69526206T2 (de) 2002-11-21
DK0739212T3 (da) 2002-06-03
ZA95463B (en) 1995-09-27
DE69526206D1 (de) 2002-05-08
JP3825043B2 (ja) 2006-09-20
EP0739212B1 (en) 2002-04-03
PT739212E (pt) 2002-08-30
IL112373A (en) 2006-08-01
IL112373A0 (en) 1995-03-30
EP0739212A1 (en) 1996-10-30
WO1995019786A1 (en) 1995-07-27
TW349021B (en) 1999-01-01
JPH09508371A (ja) 1997-08-26
US5573764A (en) 1996-11-12
CA2181568C (en) 2007-09-18
US5756085A (en) 1998-05-26

Similar Documents

Publication Publication Date Title
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
ES2152483T3 (es) Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
ES2182837T3 (es) Piran-2-onas y 5,6-dihidropiran-2-onas utiles en el tratamiento del sida y de otros retrovirus.
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
MY138883A (en) Use of asiatic acid for treatment of cencer
TR199701490A2 (xx) 3-Hidroksipiridin-2-karbonasitamidester ve bunlar�n imalat�.
MX9701385A (es) Preparacion de producto combinado para usarse en enfermedades inmunologicas.
ES2156107T3 (es) Un fgf-4 no glicosilado y composiciones que lo contienen.
IL112373A0 (en) Use of interleukin-12 to prevent graft versus host disease
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
ES2167401T3 (es) Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias.
ES2170798T3 (es) Benzopiranos y su uso como agentes terapeuticos.
GB9425730D0 (en) Compounds
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
IL131478A0 (en) Methods for treatment of scar tissue
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.
ES2153584T3 (es) Piridiniminil-1,2-benzisoxazol y -benzisotiazol como antipsicoticos.
GB9626472D0 (en) New use of comt inhibitors
BR0016616A (pt) Microrganismos atenuados para o tratamento de infecção
ES2173180T3 (es) Derivados del mercaptoacetilamida hipocolesterolemicos, antiateroescleroticos e hipotrigliceridemicos.
MX9206135A (es) Metodos